Document Detail


Coronary artery disease and prevention of heart failure.
MedLine Citation:
PMID:  15331314     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Coronary artery disease is a major contributor to the progression of left ventricular systolic dysfunction and heart failure (HF). Recognizing that coronary artery disease is a leading cause of HF in the United States is critical to reducing mortality resulting from this condition. Although some patients may be candidates for mechanical revascularization to improve left ventricular function, all patients are candidates for aggressive secondary prevention strategies. This review discusses the prevalence of coronary artery disease, prognostic significance and pathophysiology, risk factor modifications, pharmacologic treatments, and the role of revascularization.
Authors:
Liviu Klein; Mihai Gheorghiade
Related Documents :
17171904 - Revascularization of the right coronary artery: influence on thermodilution right ventr...
16684984 - Certificate of need regulations and use of coronary revascularization after acute myoca...
22924634 - Reperfusion-induced myocardial dysfunction is prevented by endogenous annexin-a1 and it...
23269534 - Anti-inflammatory effect of protocatechuic aldehyde on myocardial ischemia/reperfusion ...
17996564 - Role of right ventricular wall motion abnormalities in risk stratification and prognosi...
20345444 - Regional diastolic and systolic function by strain rate imaging for the detection of in...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  The Medical clinics of North America     Volume:  88     ISSN:  0025-7125     ISO Abbreviation:  Med. Clin. North Am.     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-08-27     Completed Date:  2004-10-14     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  2985236R     Medline TA:  Med Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1209-35     Citation Subset:  AIM; IM    
Affiliation:
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. lklein@northwestern.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Distribution
Cardiovascular Agents / therapeutic use
Chronic Disease
Coronary Artery Disease* / complications,  epidemiology,  prevention & control
Death, Sudden, Cardiac / etiology
Diabetes Complications
Disease Progression
Heart Failure* / epidemiology,  etiology,  prevention & control
Humans
Hyperlipidemias / complications
Hypertension / complications
Morbidity
Myocardial Revascularization
Obesity / complications
Practice Guidelines as Topic
Prevalence
Primary Prevention / methods*
Prognosis
Risk Factors
Risk Reduction Behavior
Smoking / adverse effects
United States
Ventricular Dysfunction, Left / etiology
Ventricular Remodeling
Grant Support
ID/Acronym/Agency:
T32 HL069771-01A1/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cardiovascular Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Feasibility of arresting the process of remodeling.
Next Document:  Preventing heart failure in patients with diabetes.